# NAD+: Research Overview — Peptide Research Alliance > A structured literature summary of NAD+ (Nicotinamide Adenine Dinucleotide): cellular mechanism, precursor supplementation (NMN, NR) clinical trials, aging biology, and safety considerations. Not a peptide; a dietary supplement. Nicotinamide Adenine Dinucleotide — the cell's core redox carrier and a consumed substrate for DNA-repair and gene-regulation enzymes; not a peptide and not a drug; a dietary supplement with an expanding human clinical trial record. ## The short version NAD+ (nicotinamide adenine dinucleotide) is the most biologically important compound on this desk — not because its human evidence is the strongest, but because it is involved in fundamentally more cellular processes than any of the peptides alongside it. Every living cell contains NAD+; it is the central carrier of electrons in energy metabolism and the substrate consumed by a group of enzymes — sirtuins, PARPs, and CD38 — that govern DNA repair, gene regulation, and inflammatory signaling [26]. The aging context: tissue NAD+ levels decline with age [26]. This decline has generated a field of precursor supplementation research using compounds that the cell converts to NAD+: chiefly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Controlled human trials have demonstrated that oral NMN and NR reliably raise blood NAD+ [24][27], and a multicenter RCT of NMN found improvements in walking distance and quality-of-life scores alongside NAD+ elevation [24]. A 2025 review in Nature Metabolism concluded, however, that translation to hard clinical outcomes remains inconsistent, and tissue-specific NAD+ dynamics in humans are incompletely characterized [23]. NAD+ is not a peptide and not a drug. It is classified as a dietary supplement in most markets (though the FDA has contested NMN's supplement status). This page summarizes the published evidence; it does not constitute medical advice and lists no doses. ## What it is NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a dinucleotide — specifically, nicotinamide mononucleotide and adenosine monophosphate joined by two bridging phosphate groups, with a pyridine nicotinamide ring and an adenine ring. Molecular formula C21H27N7O14P2. It alternates between the oxidized form (NAD+) and the reduced form (NADH) as it shuttles electrons through metabolic reactions. Also known as Coenzyme I and historically as DPN (diphosphopyridine nucleotide). Distinct from its precursors, which are separate molecular entities: **NMN** (nicotinamide mononucleotide) and **NR** (nicotinamide riboside) are the oral forms most studied in clinical trials, because oral NAD+ itself is poorly absorbed intact by most cells. NAD+ as a direct product is also used in intravenous infusion therapy in wellness contexts, though this route has minimal controlled evidence and has been subject to FDA recalls for compounded products with elevated endotoxin levels. ## How it works NAD+ serves two distinct cellular roles [26]: **1. Redox electron carrier.** NAD+/NADH is the primary electron shuttle in glycolysis, the TCA (citric acid) cycle, and oxidative phosphorylation — the core of ATP energy production in mitochondria. Inadequate NAD+ constrains the throughput of these reactions. **2. Consumed signaling substrate.** Three enzyme classes consume NAD+ as a substrate (breaking the N-glycosidic bond) rather than simply using it as a cofactor: - **Sirtuins (SIRT1–SIRT7):** NAD+-dependent deacylases and deacetylases that regulate gene expression, mitochondrial biogenesis, DNA repair, and inflammatory signaling. - **PARPs (poly(ADP-ribose) polymerases):** DNA-damage-response enzymes; PARP1 is the dominant NAD+ consumer during genotoxic stress. - **CD38/CD157:** NAD+-consuming ectoenzymes that rise with age and inflammatory states; the age-associated rise in CD38 is one proposed driver of the decline in tissue NAD+. The rate-limiting salvage enzyme **NAMPT** (nicotinamide phosphoribosyltransferase) regenerates NAD+ from nicotinamide; its activity declines with age and metabolic dysfunction. The therapeutic rationale for NMN and NR supplementation is that both bypass the NAMPT step and enter the NAD+ synthesis pathway upstream of the rate-limiting point. ## What the research shows **Multicenter double-blind NMN RCT (healthy middle-aged adults, 2023) [24]:** Oral NMN at 300–900 mg/day for 60 days dose-dependently raised blood NAD+ (p ≤ 0.001 across all NMN groups versus placebo at days 30 and 60); 600 mg/day was identified as the optimal dose. Walking distance and quality-of-life scores improved in NMN versus placebo groups. A biological age measure did not increase. No safety issues at any dose. **NMN and muscle insulin sensitivity (postmenopausal women with prediabetes, 2021) [25]:** 10 weeks of oral NMN at 250 mg/day significantly improved muscle insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp and remodeled insulin signaling pathways in skeletal muscle. No change in body composition or HbA1c. **NAD+ metabolism and aging biology (review, 2021) [26]:** Foundational synthesis identifying sirtuins, PARP1, and CD38/CD157 as the major competing consumers of the NAD+ pool. Documents declining NAD+ with age across model organisms and humans; frames NAD+ restoration as a candidate strategy against age-related disease. **NR dose-response safety and NAD+ elevation (overweight adults, 2019) [27]:** NR at 100, 300, and 1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively. No flushing; no significant adverse-event differences from placebo at any dose; no elevation of LDL cholesterol; no disruption of 1-carbon metabolism. **2025 human-evidence synthesis (Nature Metabolism) [23]:** Reviewed the human clinical evidence on NAD+ precursor supplementation in aging. Conclusions: blood NAD+ elevation is consistently demonstrated; translation to clinical endpoints is inconsistent; tissue-specific NAD+ dynamics in humans are incompletely characterized; more clinical studies are needed rather than reliance on rodent extrapolation. ## Reported effects, cautions, and safety NAD+ and its precursors are predominantly used as dietary supplements rather than via the research-peptide community pathways, so the anecdotal-signal profile here is different from the other compounds on this desk. The research.json for this compound records no community-signal entries; we follow that record. Safety considerations from the published literature and regulatory record: - *Oral NAD+ itself is poorly cell-bioavailable:* Most experts consider oral NAD+ capsules less rational than precursors (NMN or NR), which bypass cellular uptake barriers. A significant share of oral NAD+ is degraded before reaching target cells. - *Blood NAD+ elevation is demonstrated; hard clinical outcomes are not:* The 2025 Nature Metabolism review [23] found human efficacy data limited and tissue NAD+ dynamics sparse. Claimed longevity, disease-prevention, or anti-aging effects are not established in human trials. - *Theoretical cancer concern:* NAD+ supports proliferating cells' metabolic demands; raising NAD+ levels has dual, context-dependent roles in oncology. Caution is reasonable in cancer populations. - *IV NAD+ wellness therapy:* Aggressive marketing, minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma; infusions can cause chest discomfort, abdominal cramping, flushing, and nausea if administered too quickly. The FDA has issued a Class I recall of a compounded injectable NAD+ product for elevated bacterial endotoxin. - *NMN regulatory uncertainty:* The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug, creating marketplace uncertainty for NMN-containing products. - *Supplement product quality:* As with all dietary supplements, third-party testing is not required; actual content and purity vary. NR's safety profile at the doses tested in clinical trials (up to 1000 mg/day for 8 weeks) was favorable [27]. ## Where it fits in this research desk NAD+ occupies a conceptually distinct position on this desk: it is not a peptide, not an investigational drug, not a research chemical — it is an endogenous coenzyme that the body makes continuously and that declines with aging. Its inclusion reflects its role as the longevity-biology anchor of this hub: the compound that connects cellular energy, DNA repair, and gene regulation in a single pathway, and whose precursor supplementation is the subject of the largest body of controlled human research among the five compounds here. The comparison with the four peptides is instructive: NAD+ precursors have the most controlled human trial volume (multiple double-blind RCTs); but the human-to-clinical-outcomes translation gap is as large here as anywhere on this desk. Raising blood NAD+ is not the same as extending health or reversing aging, and the 2025 evidence synthesis [23] states this plainly. [Compare all five compounds](/compare) for a systematic view of how each sits against that standard. --- An independent literature digest of peer-reviewed research — definitional, cited, and free of products, prescriptions, and dosing recommendations.